Lilly will test its weight loss drug directly against Novo Nordisk's Wegovy
With tens of billions of dollars on the line and people scrambling to get the drug, Eli Lilly is planning to start testing its weight loss treatment candidate in a head-to-head clinical trial against Novo Nordisk’s Wegovy this month.
Lilly is planning to seek a fast-track label expansion for its type 2 diabetes drug Mounjaro (tirzepatide) to include obesity. Pitting it directly against its competitor could give prescribers insight into which drug is better for patients. The 700-person Phase IIIb clinical trial, dubbed SURMOUNT-5, is slated to wrap up in February 2025, according to a new study listed last Friday on clinicaltrials.gov. It was first reported by Fierce Pharma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
